Levetiracetam
Product Images NDC 42254-056

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 42254-056). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 01)

Chemical structure of levetiracetam showing its molecular arrangement with a pyrrolidone ring attached to an ethyl side chain and amide group.*

FDA Label Image

Posfig1 (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 02)

A bar graph comparing the percentage of patients receiving placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The graph shows 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day, with the latter two marked as statistically significant versus placebo.*

FDA Label Image

Posfig2 (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 03)

A vertical bar graph comparing the percentage of patients with a specific response among three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The graph shows increasing response rates from placebo (6.3%) to 1000 mg/day (20.8%) and 2000 mg/day (35.2%), with statistical significance indicated for both Levetiracetam groups versus placebo.*

FDA Label Image

Posfig3 (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 04)

Bar chart comparing the percentage of patients between placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The Levetiracetam group shows a higher percentage of patients at 39.4% versus 14.4% for placebo, with a noted statistical significance.*

FDA Label Image

Posfig4 (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 05)

Bar chart comparing the percentage of patients responding to Placebo and Levetiracetam treatments. The chart shows 19.6% for Placebo (N=97) and 44.6% for Levetiracetam (N=101), illustrating a higher response rate for Levetiracetam.*

FDA Label Image

Pgtcfig1 (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 06)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The vertical axis represents the percentage of patients from 0% to 100%. The placebo group (N=84) shows 45.2%, while the Levetiracetam group (N=79) shows 72.2%, with a note indicating statistical significance versus placebo.*

FDA Label Image

Levetiracetam 500mg (Eb02779c Acdc 48ed 9d23 Ca39ba152d0d 07)

Levetiracetam 500 mg tablets label from Rebel Distributors Corp, NDC 42254-056-60, showing 60 tablets per bottle. The label includes the product ID QL005660CA, dosage strength, physical description of the tablet as orange colored, film coated, oblong with specific debossing, and storage instructions to keep at controlled room temperature 15°-30°C (59°-86°F). Packaged by Physician Partner, Thousand Oaks, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.